|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OVOL2 |
Gene summary for OVOL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OVOL2 | Gene ID | 58495 |
| Gene name | ovo like zinc finger 2 | |
| Gene Alias | CHED | |
| Cytomap | 20p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9BRP0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 58495 | OVOL2 | HTA11_78_2000001011 | Human | Colorectum | AD | 5.03e-03 | 3.97e-01 | -0.1088 |
| 58495 | OVOL2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.93e-07 | 4.34e-01 | -0.1954 |
| 58495 | OVOL2 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.65e-03 | 4.34e-01 | -0.1464 |
| 58495 | OVOL2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.83e-02 | 3.43e-01 | -0.059 |
| 58495 | OVOL2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.24e-02 | -2.31e-01 | 0.294 |
| 58495 | OVOL2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.29e-17 | 1.11e+00 | 0.281 |
| 58495 | OVOL2 | A015-C-203 | Human | Colorectum | FAP | 2.43e-11 | -2.28e-01 | -0.1294 |
| 58495 | OVOL2 | A002-C-201 | Human | Colorectum | FAP | 7.45e-04 | -1.08e-01 | 0.0324 |
| 58495 | OVOL2 | A001-C-108 | Human | Colorectum | FAP | 1.90e-05 | -1.68e-01 | -0.0272 |
| 58495 | OVOL2 | A002-C-205 | Human | Colorectum | FAP | 3.76e-07 | -1.64e-01 | -0.1236 |
| 58495 | OVOL2 | A015-C-006 | Human | Colorectum | FAP | 1.35e-05 | -2.62e-01 | -0.0994 |
| 58495 | OVOL2 | A015-C-106 | Human | Colorectum | FAP | 1.71e-02 | -6.82e-02 | -0.0511 |
| 58495 | OVOL2 | A002-C-114 | Human | Colorectum | FAP | 2.52e-05 | -1.97e-01 | -0.1561 |
| 58495 | OVOL2 | A015-C-104 | Human | Colorectum | FAP | 2.82e-09 | -2.28e-01 | -0.1899 |
| 58495 | OVOL2 | A001-C-014 | Human | Colorectum | FAP | 1.82e-03 | -2.04e-01 | 0.0135 |
| 58495 | OVOL2 | A002-C-016 | Human | Colorectum | FAP | 1.41e-06 | -2.18e-01 | 0.0521 |
| 58495 | OVOL2 | A015-C-002 | Human | Colorectum | FAP | 1.03e-02 | -2.44e-01 | -0.0763 |
| 58495 | OVOL2 | A002-C-116 | Human | Colorectum | FAP | 2.74e-11 | -2.25e-01 | -0.0452 |
| 58495 | OVOL2 | A014-C-008 | Human | Colorectum | FAP | 1.51e-04 | -2.30e-01 | -0.191 |
| 58495 | OVOL2 | A018-E-020 | Human | Colorectum | FAP | 1.28e-07 | -2.79e-01 | -0.2034 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0001667 | Colorectum | AD | ameboidal-type cell migration | 137/3918 | 475/18723 | 2.17e-05 | 4.33e-04 | 137 |
| GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
| GO:0001890 | Colorectum | AD | placenta development | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
| GO:0001892 | Colorectum | AD | embryonic placenta development | 33/3918 | 82/18723 | 5.30e-05 | 9.01e-04 | 33 |
| GO:0060562 | Colorectum | AD | epithelial tube morphogenesis | 93/3918 | 325/18723 | 5.65e-04 | 6.00e-03 | 93 |
| GO:0060711 | Colorectum | AD | labyrinthine layer development | 19/3918 | 44/18723 | 7.13e-04 | 7.21e-03 | 19 |
| GO:0050673 | Colorectum | AD | epithelial cell proliferation | 119/3918 | 437/18723 | 8.75e-04 | 8.51e-03 | 119 |
| GO:0007178 | Colorectum | AD | transmembrane receptor protein serine/threonine kinase signaling pathway | 99/3918 | 355/18723 | 9.92e-04 | 9.28e-03 | 99 |
| GO:0014020 | Colorectum | AD | primary neural tube formation | 33/3918 | 94/18723 | 1.02e-03 | 9.50e-03 | 33 |
| GO:0061458 | Colorectum | AD | reproductive system development | 116/3918 | 427/18723 | 1.11e-03 | 1.01e-02 | 116 |
| GO:0001841 | Colorectum | AD | neural tube formation | 35/3918 | 102/18723 | 1.16e-03 | 1.05e-02 | 35 |
| GO:0043616 | Colorectum | AD | keratinocyte proliferation | 19/3918 | 46/18723 | 1.36e-03 | 1.19e-02 | 19 |
| GO:0071559 | Colorectum | AD | response to transforming growth factor beta | 74/3918 | 256/18723 | 1.45e-03 | 1.23e-02 | 74 |
| GO:0048608 | Colorectum | AD | reproductive structure development | 114/3918 | 424/18723 | 1.78e-03 | 1.47e-02 | 114 |
| GO:0071560 | Colorectum | AD | cellular response to transforming growth factor beta stimulus | 72/3918 | 250/18723 | 1.85e-03 | 1.52e-02 | 72 |
| GO:0060390 | Colorectum | AD | regulation of SMAD protein signal transduction | 14/3918 | 31/18723 | 2.10e-03 | 1.67e-02 | 14 |
| GO:0010837 | Colorectum | AD | regulation of keratinocyte proliferation | 15/3918 | 35/18723 | 2.78e-03 | 2.09e-02 | 15 |
| GO:0060395 | Colorectum | AD | SMAD protein signal transduction | 28/3918 | 82/18723 | 3.73e-03 | 2.63e-02 | 28 |
| GO:0035148 | Colorectum | AD | tube formation | 45/3918 | 148/18723 | 4.13e-03 | 2.87e-02 | 45 |
| GO:0001838 | Colorectum | AD | embryonic epithelial tube formation | 38/3918 | 121/18723 | 4.40e-03 | 3.01e-02 | 38 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| OVOL2 | MAIT | Colorectum | SER | B3GALT5,STAP2,SASS6, etc. | 1.43e-02 |  |
| OVOL2 | INFIB | Prostate | ADJ | OXSM,MXD3,ANKRD36C, etc. | 7.46e-02 |  |
| OVOL2 | INFIB | Prostate | BPH | OXSM,MXD3,ANKRD36C, etc. | 1.89e-01 |  |
| OVOL2 | PMC | Stomach | CAG with IM | LYPD6B,SYTL2,DHX16, etc. | 2.14e-01 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OVOL2 | SNV | Missense_Mutation | novel | c.749T>C | p.Leu250Pro | p.L250P | Q9BRP0 | protein_coding | deleterious(0.01) | probably_damaging(0.963) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| OVOL2 | insertion | Frame_Shift_Ins | novel | c.664_665insGCAGTAGGGTC | p.Thr222SerfsTer16 | p.T222Sfs*16 | Q9BRP0 | protein_coding | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| OVOL2 | insertion | Frame_Shift_Ins | novel | c.332_333insAT | p.Thr112SerfsTer24 | p.T112Sfs*24 | Q9BRP0 | protein_coding | TCGA-B6-A0IM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| OVOL2 | insertion | Nonsense_Mutation | novel | c.331_332insAATCGCTTGAACCTGGGAGGCGGAGGTTGCAGTGAGCCAA | p.Gly111GlufsTer12 | p.G111Efs*12 | Q9BRP0 | protein_coding | TCGA-B6-A0IM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| OVOL2 | SNV | Missense_Mutation | c.481N>C | p.Asp161His | p.D161H | Q9BRP0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR | |
| OVOL2 | SNV | Missense_Mutation | c.343G>A | p.Asp115Asn | p.D115N | Q9BRP0 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-JW-A5VG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| OVOL2 | SNV | Missense_Mutation | rs368800012 | c.407N>A | p.Arg136His | p.R136H | Q9BRP0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| OVOL2 | SNV | Missense_Mutation | novel | c.701A>G | p.Asn234Ser | p.N234S | Q9BRP0 | protein_coding | tolerated(0.32) | benign(0.034) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| OVOL2 | SNV | Missense_Mutation | novel | c.527N>G | p.Lys176Arg | p.K176R | Q9BRP0 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| OVOL2 | SNV | Missense_Mutation | novel | c.674C>G | p.Thr225Ser | p.T225S | Q9BRP0 | protein_coding | tolerated(0.69) | benign(0.047) | TCGA-A5-A2K2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |